



nucware.com, LLC
Product Demo

Anytown Cardiac Specialists, Inc.

Janet Jones, MD, FACC
Ed Wilson, MD, FACC

Tom Smith, MD, FACC
Jim Wilson, MD, FACC
John Womack, MD, FACC

JOHNSON, VICTOR	DOB: 09/06/1938	January 24, 2012
------------------------	------------------------	-------------------------

INTRAVENOUS ADENOSINE MYOCARDIAL PERFUSION STUDY

(rest/pharmacologic stress SPECT with gated SPECT wall motion studies at rest and post-stress)

Ordering Physician: Ed Wilson, MD, FACC

Clinical History: 73 year-old man with cardiac risk factors which include gender, age, known CAD, current smoking, and peripheral vascular disease. The patient has a history of coronary artery bypass graft surgery. Significant pre-test symptoms include chest pain. His last Beta-blocker was administered 26 hours prior to the study. His height is 70 inches and weight is 148 lbs, with a BMI of 21 (BSA: 1.8 m²).

Indications for study: Chest pain, known CAD (diagnostic and prognostic assessment), coronary artery bypass graft surgery, and pre-operative evaluation. **Pharmacologic indication:** Physician request.

ADENOSINE PHARMACOLOGIC STRESS

BASELINE ECG: Sinus bradycardia at 54 bpm. PR: 0.210, QRS: 0.080, QT: 0.400, and Axis: -30. No arrhythmias. ST: non-specific ST-T changes were noted. T waves: non-specific T wave changes were noted. QRS (Q waves): normal. Conduction: normal. INTERPRETATION: Abnormal ECG as described.

Adenosine was infused over 5 minutes at a maximum rate of 140 mcg/kg/min (total dose 47.1 mg) to a peak heart rate of 104 bpm (71% MPHR). BP decreased from 136/80 to 114/64 at peak stress. STRESS ECG: Sinus tachycardia. No arrhythmias during stress or recovery. No ischemic ST-T changes. Conduction: normal. Testing was supervised and interpreted by Ed Wilson, MD, FACC.

IMPRESSION:

1. Appropriate blood pressure response to intravenous adenosine.
2. Appropriate heart rate response to intravenous adenosine.
3. Patient reported dyspnea and headache.
4. Negative ECG for ischemia.
5. No arrhythmias during adenosine infusion.

MYOCARDIAL PERFUSION IMAGING

30 minutes following the intravenous administration of 6.80 mCi of ^{99m}Tc sestamibi, resting gated SPECT myocardial perfusion imaging was performed from the RAO to LPO positions, with the patient placed in the supine position. Subsequently, adenosine was infused and 36.00 mCi of ^{99m}Tc sestamibi was injected intravenously. 70 minutes later, post-infusion gated SPECT myocardial perfusion imaging was performed from the RAO to LPO positions, with the patient placed in the supine and (non-gated) prone positions.

Myocardial Perfusion: **NORMAL**

Summed stress score (SSS) = **0**. Summed rest score (SRS) = **0**. Summed difference score (SDS) = **0**, a negative study for reversible perfusion abnormality.

The overall technical quality of the study is good.

IMPRESSION:

1. No evidence of adenosine-induced reversible perfusion abnormality.
2. No evidence of prior myocardial infarction.
3. Gated SPECT wall motion study at rest demonstrates mild global hypokinesis with EF = 46% and mildly enlarged ESV = 76 cc. Gated SPECT wall motion study at 70 minutes post-stress demonstrates similar wall motion with EF = 45% and mildly enlarged ESV = 72 cc.
4. The probability of a hemodynamically significant coronary artery stenosis is considered to be low (<10% probability). This negative study for reversible perfusion abnormality combined with a mildly reduced post-stress EF and mildly enlarged post-stress ESV predicts a low risk of cardiac mortality over the next 1-2 years. Clinical correlation is required.



Ed Wilson, MD, FACC
(01/25/2012)




TABLE 1: Perfusion Scores (17-segment model)

SAX APICAL				SAX MID				SAX BASAL				APEX			
	#	S	R		#	S	R		#	S	R		#	S	R
ANT	13	0	0	ANT	7	0	0	ANT	1	0	0	APX	17	0	0
SEP	14	0	0	A-S	8	0	0	A-S	2	0	0				
INF	15	0	0	I-S	9	0	0	I-S	3	0	0				
LAT	16	0	0	INF	10	0	0	INF	4	0	0				
				I-L	11	0	0	I-L	5	0	0				
				A-L	12	0	0	A-L	6	0	0				

TABLE 2: Perfusion Score Legend

Score	Meaning
0	Normal
1	Mildly Reduced/Equivocal
2	Moderately Reduced
3	Severely Reduced
4	Absent Uptake

TABLE 3: Observed vs. Expected Volumes and EF

	Observed (STRESS)	Expected (STRESS)
EDV	130 cc	<= 136 cc (75 cc/m ²)
ESV	72 cc	<= 71 cc (39 cc/m ²)
EF	45%	>= 50%

NAME: JOHNSON, VICTOR
 DOB: 09/06/1938
 Study Date: 1/24/12
 MRN: _____
 Cardiologist/
 Ordering MD: E. WILSON
 Primary MD: _____
 CC TO: _____
 ID VERIFIED BY: WW

I.V. Adenosine

MYOCARDIAL PERFUSION STUDY PHYSICIAN WORKSHEET

Risk Factors

- CAD, Known
- CAD, Family History
- Diabetes
- ED
- Hyperlipidemia
- Hypertension
- Metabolic Syndrome
- Obesity
- PAD
- Renal Failure
- Smoking, Current

Cardiac History Study Indications

- Abnormal ECG
- Abnormal Stress Echo
- Abnormal Treadmill
- Arrhythmias, Atrial
- Arrhythmias, Ventricular
- Cardiomyopathy
- CHF
- CAD, Known
- Prior MI
- Prior PCI-Stent
- Prior CABG
- Viability Study

Pre-Test Symptoms Study Indications

- Chest Pain NOS
- Angina, Typical
- Angina, Atypical
- Anginal Equivalent
- Non-anginal Chest Pain
- Dyspnea
- Syncope

Special Conditions

- Asthma
- Inhalers
- Defibrillator
- Pacemaker

Other Indications

- Pre-Op Eval

Pharm. Indication

Last β -blocker: 26 hrs ago
 Height: 70 inches Gender: M F
 Weight: 148 lbs

DATA	STRESS	RECOVERY	Age: <u>73</u> ; MPHR is _____ bpm; 85% of MPHR is _____ bpm.
	BP <u>136/80</u> HR <u>84</u>	BP <u>118/74</u> HR <u>102</u>	Infusion rate: <u>140</u> μ g/kg/minute
0 min.	<u>128/82</u> <u>90</u>	imed.	Total dose: <u>47.4</u> mg (\leq 90mg)
1 min.	<u>124/76</u> <u>92</u>	2 min.	Total infusion time: <u>05:00</u>
2 min.	<u>118/70</u> <u>98</u>	4 min.	Isotope injected at <u>02:35 @ 94</u> bpm
3 min.	<u>114/69</u> <u>104</u>	6 min.	The patient:
4 min.		BP PEAK STRESS: <u>114/64</u>	<input type="checkbox"/> exercised at _____ mph and _____ % grade for _____ minutes
5 min.		HR PEAK STRESS: <u>104</u>	<input checked="" type="checkbox"/> did not exercise
6 min.			

Baseline ECG
S. B rhythm at 54 bpm
 PR: .21 seconds QRS: .08 seconds
 QT: .40 seconds Axis: -30 degrees
 normal
 Arrhythmias: _____
 ST: normal Early Repol
 depressed in leads _____
 elevated in leads _____
 Non-Specific ST Abnormality
 T waves: normal Flat Tall
 biphasic in leads _____
 inverted in leads _____
 Non-Specific T Abnormality
 QRS: normal Abnormal ECG due to: _____
 Baseline ECG Interpretation
 (A) Conduction Abnormalities: Normal ECG Abnormal ECG due to: _____
 (B) Q Waves: _____ Borderline ECG due to: _____

Test Terminated Due To:

- Infusion Complete
- _____

IMPRESSION

1. Appropriate Paradoxical Increased
 Blunted Hypotensive **BP response**
2. Appropriate Exaggerated Increased
 Blunted **HR response**
3. Negative Equivocal **ECG for ischemia.**
 Positive Uninterpretable
4. No arrhythmias V. couplets
 PAC's PVC's V. tach. (____ beats)
 during after adenosine infusion.

5. Patient Noted:
- No symptoms
 - Chest pain/discomfort
 - General malaise
 - Nausea
 - Dyspnea
 - Headache
 - Lightheadedness

6. Aminophylline _____ mg administered starting _____:_____ after isotope injection.
7. _____

Stress ECG Rhythm ST Arrhythmia _____
 No ischemic ST-T changes
 ST segment depression up to _____ mm with:
 upsloping
 horizontal configuration in leads _____
 downsloping
 ST segment elevation of _____ mm in leads _____
 New Conduction ABNL: _____
 New T Wave ABNL: _____

Recovery ECG Comments: _____

Ed Wilson
 MD/PA/NP signature

TECHNOLOGIST WORKSHEET

Name: JOHNSON, VICTOR DOB: 09/06/1938

Study Date: 01 / 24 / 2002
MM DD YYYY

Patient ID on Modality: _____

Study Type: ADENO MPF

Female patient bra/cup size: _____ / _____

Breast Surgery: YES / NO

Location: LEFT / RIGHT

Patient's Height: 70 inches

Weight: 148 lbs

Describe: _____

Gender: Male Female

REST IMAGING

REST DOSE: 6.8 mCi

INJECTION TIME: 11 HH : 10 MM

SCAN START TIME: 11 HH : 40 MM

Pharmaceutical: Sestamibi
 Tetrofosmin
 Rubidium-82
 Thallium

Rejected / Total Beats: 0 / 1
Basketball Motion: YES / NO
Upward Creep: YES / NO
Acq. Gating Failure: YES / NO

MoCo estimate from review of raw REST data:

NONE MODERATE*
 MILD SEVERE*

STRESS IMAGING

STRESS DOSE: 36.0 mCi

INJECTION TIME: 12 HH : 40 MM

SCAN START TIME: 13 HH : 50 MM

Pharmaceutical: Sestamibi
 Tetrofosmin
 Rubidium-82
 Thallium

Rejected / Total Beats: _____ / _____
Basketball Motion: YES / NO
Upward Creep: YES / NO
Acq. Gating Failure: YES / NO

MoCo estimate from review of raw STRESS data:

NONE MODERATE*
 MILD SEVERE*

*** Note: Moderate or Severe cardiac motion requires IMMEDIATE repeat imaging.**

Stress prone imaging performed: YES / NO

Notes: _____

Attenuation correction: _____

Repeat imaging start times:

_____ HH : _____ MM REST / STRESS

_____ HH : _____ MM REST / STRESS

X _____
Technologist initials

PERFUSION RESULTS

Name: JOHNSON, VICTOR DOB: 09, 06, 1938

Prone performed: YES / NO

SSS: 0

SRS: 0

SDS: 0

TID ratio: 1.10

TID is abnormal

STRESS

All 0

REST

All 0

Perfusion Results:

Normal

Abnormal

LVH


RVE

RVH

Attenuation

BREAST

INFERIOR




	SEGMENTAL PERFUSION DEFECTS						TYPE	EXTENT	SEVERITY	CVT	
A	BASAL	A	AS	IS	I	IL	AL	REVERSIBLE	SMALL	MILD	LAD
	MID	A	AS	IS	I	IL	AL				DIAGONAL
	APICAL	A	S	I	L			PERSISTENT	MEDIUM	MODERATE	LCX
	APEX			APEX				MIXED	LARGE	SEVERE	RCA/PDA
B	BASAL	A	AS	IS	I	IL	AL	REVERSIBLE	SMALL	MILD	LAD
	MID	A	AS	IS	I	IL	AL				DIAGONAL
	APICAL	A	S	I	L			PERSISTENT	MEDIUM	MODERATE	LCX
	APEX			APEX				MIXED	LARGE	SEVERE	RCA/PDA
C	BASAL	A	AS	IS	I	IL	AL	REVERSIBLE	SMALL	MILD	LAD
	MID	A	AS	IS	I	IL	AL				DIAGONAL
	APICAL	A	S	I	L			PERSISTENT	MEDIUM	MODERATE	LCX
	APEX			APEX				MIXED	LARGE	SEVERE	RCA/PDA
D	BASAL	A	AS	IS	I	IL	AL	REVERSIBLE	SMALL	MILD	LAD
	MID	A	AS	IS	I	IL	AL				DIAGONAL
	APICAL	A	S	I	L			PERSISTENT	MEDIUM	MODERATE	LCX
	APEX			APEX				MIXED	LARGE	SEVERE	RCA/PDA

FUNCTION RESULTS

Name: JOHNSON, VICTOR DOB: 09, 06, 1938


EDV: 130 **STRESS**
 ESV: 72 GATING NOT DONE
 EF: 45

- Global Hypokinesis { MILD
 MODERATE
 SEVERE
 Stunning
 Dyssynchronous { CABG
 PACED
 LBBB



EDV: 140 **REST**
 ESV: 76 GATING NOT DONE
 EF: 46

- Global Hypokinesis { MILD
 MODERATE
 SEVERE
 CABG
 Dyssynchronous { PACED
 LBBB



ISCHEMIC CARDIOMYOPATHY NON-ISCHEMIC CARDIOMYOPATHY

Current probability of a hemodynamically significant coronary artery stenosis: < 10% ≥ 90% ≥ 99%
 60% - 89% ≥ 95%

PREDICTED STENOSES

	UNSPECIFIED	LAD		UNSPECIFIED	LAD
A	MILD to MODERATE	DIAGONAL	C	MILD to MODERATE	DIAGONAL
	MODERATE to SEVERE	LCX		MODERATE to SEVERE	LCX
	SEVERE to CRITICAL	RCA/PDA		SEVERE to CRITICAL	RCA/PDA
B	MILD to MODERATE	DIAGONAL	D	MILD to MODERATE	DIAGONAL
	MODERATE to SEVERE	LCX		MODERATE to SEVERE	LCX
	SEVERE to CRITICAL	RCA/PDA		SEVERE to CRITICAL	RCA/PDA

OVERRIDE AUTOMATIC CALCULATIONS:

STRESS		REST	
ESV	EF	ESV	EF
NORMAL	NORMAL	NORMAL	NORMAL
ELEVATED	REDUCED	ELEVATED	REDUCED
MARKEDLY ELEVATED	SEVERELY REDUCED	MARKEDLY ELEVATED	SEVERELY REDUCED

Add to impression:

Risk of cardiac mortality within next 1 to 2 years:
 Very Low Intermediate
 Low High